Teresa Leonardo Alves
Biographic Data
| ID | 1780228 |
|---|---|
| NAME | Teresa Leonardo Alves |
| GIVEN NAMES | Teresa Leonardo |
| FAMILY NAME | Alves |
| SIGNATURE | ALVES T L |
| AFFILIATIONS | Utrecht Institute for Pharmaceutical Sciences, Netherlands |
| ORCID | 0000-0003-4967-1916 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2017 |
| LATEST PUBLICATION YEAR | 2019 |
| H-INDEX | 0 |
Added therapeutic value of new drugs approved in Brazil from 2004 to 2016
This study aimed to assess the level of therapeutic innovation of new drugs approved in Brazil over 13 years and whether they met public health needs. Comparative descriptive analysis of therapeutic value assessments performed by the Brazilian Chamber of Drug Market Regulation (CMED) and the French drug bulletin Prescrire for new drugs licensed in Brazil, from January 1st 2004 to December 31st 2016. The extent to which new drugs met public health…
Disease awareness campaigns in printed and online media in Latvia: Cross-sectional study on consistency with WHO ethical criteria for medicinal drug promotion and European standards
The compliance of disease awareness campaigns in Latvian media with international and European standards is low. This raises concerns about the nature of information being conveyed. Through lack of balance, missing sponsorship information, and misleading or incomplete information, these campaigns could contribute to inaccurate self-diagnosis and generate demand among those who might not need medical treatment
The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries
Whilst national guidelines recognize the relevance of QoL to determine the relative effectiveness of new anti-cancer drugs, this is not well-reflected in current assessments. Developing and implementing into REAs specific evidence requirements for QoL data would improve the use of this patient-centred outcome in future reimbursement and pricing decisions
No prominent works on this page.
The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries
Whilst national guidelines recognize the relevance of QoL to determine the relative effectiveness of new anti-cancer drugs, this is not well-reflected in current assessments. Developing and implementing into REAs specific evidence requirements for QoL data would improve the use of this patient-centred outcome in future reimbursement and pricing decisions
Disease awareness campaigns in printed and online media in Latvia: Cross-sectional study on consistency with WHO ethical criteria for medicinal drug promotion and European standards
The compliance of disease awareness campaigns in Latvian media with international and European standards is low. This raises concerns about the nature of information being conveyed. Through lack of balance, missing sponsorship information, and misleading or incomplete information, these campaigns could contribute to inaccurate self-diagnosis and generate demand among those who might not need medical treatment
Added therapeutic value of new drugs approved in Brazil from 2004 to 2016
This study aimed to assess the level of therapeutic innovation of new drugs approved in Brazil over 13 years and whether they met public health needs. Comparative descriptive analysis of therapeutic value assessments performed by the Brazilian Chamber of Drug Market Regulation (CMED) and the French drug bulletin Prescrire for new drugs licensed in Brazil, from January 1st 2004 to December 31st 2016. The extent to which new drugs met public health…
Environmental health (3 works) · Health Systems, Economic Evaluations, Quality of Life (3 works) · Medicine (3 works) · Pharmaceutical Economics and Policy (3 works) · Public health (3 works) · Disease (2 works) · Family medicine (2 works) · Internal Medicine (2 works) · Nursing (2 works) · Pathology (2 works)